Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

Haematological malignancies were previously thought to be driven solely by genetic or
epigenetic lesions within haematopoietic cells. However, the niches that maintain and …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

The human blood system is maintained through the differentiation and massive amplification
of a limited number of long-lived haematopoietic stem cells (HSCs). Perturbations to this …

Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic
cells driven by somatic gene mutations. Although assessment of morphology plays a crucial …

Somatic mutations drive the development of cancer and may contribute to ageing and other
diseases,. Despite their importance, the difficulty of detecting mutations that are only present …

Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …

Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …

Over the course of an individual's lifetime, normal human cells accumulate mutations. Here
we compare the mutational landscape in 29 cell types from the soma and germline using …

The use of liquid biopsies for cancer detection and management is rapidly gaining
prominence. Current methods for the detection of circulating tumour DNA involve …